Sickle cell disease (SCD) is the most common monogenic disorder in the world. Notably, there is extensive clinical heterogeneity in SCD that cannot be fully accounted for by known factors, and in particular, the extent to which the phenotypic diversity of SCD can be explained by genetic variation has not been reliably quantified. Here, in a family-based cohort of 449 patients with SCD and 755 relatives, we first show that 5 known modifiers affect 11 adverse outcomes in SCD to varying degrees. We then utilize a restricted maximum likelihood procedure to estimate the heritability of 20 hematologic traits, including fetal hemoglobin (HbF) and white blood cell count (WBC), in the clinically relevant context of inheritance from healthy carriers to SCD patients. We report novel estimations of heritability for HbF at 31.6% (±5.4%) and WBC at 41.2% (±6.8%) in our cohort. Finally, we demonstrate shared genetic bases between HbF, WBC, and other hematologic traits, but surprisingly little overlap between HbF and WBC themselves. In total, our analyses show that HbF and WBC have significant heritable components among individuals with SCD and their relatives, demonstrating the value of using family-based studies to better understand modifiers of SCD.
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| INTRODUCTION
Sickle cell disease (SCD), caused by the substitution of valine for glutamic acid in the β-globin chain of adult hemoglobin (HbA), is the most common monogenic disorder in the world. Under conditions of deoxygenation, mutated sickle hemoglobin (HbS) polymerizes and damages erythrocytes, leading to vaso-occlusive events and hemolytic anemia. HbA < 30% and HbS < 30% were excluded.
After passing inclusion and exclusion criteria, there were a total of 449 individuals with SCD, 587 with sickle cell trait, and 174 with normal HbA (Appendix, Figure S1 in Supporting Information). Ethylenediaminetetraacetic acid blood samples were used for measurements of complete blood counts. Levels of different hemoglobin types were measured via hemoglobin electrophoresis.
| Statistical analysis
Statistical analyses were performed with R 3.5.1 and conducted using approaches described in the Appendix in Supporting Information. 
| RESULTS
FIGURE 1 Effects of 5 risk factors on 11 markers of sickle cell morbidity. Odds ratios (OR) and 95% confidence interval bounds for the effects of high (A) fetal hemoglobin, (B) white blood cell count (WBC), (C) hematocrit, (D) systolic blood pressure, (E) and cigarette smoking on 11 markers of SCD morbidity: low hematocrit, history of blood transfusions, pain crisis, acute chest syndrome, high WBC, leg ulcers, aseptic necrosis of the hip or shoulder, priapism, retinopathy, cholecystectomy, and stroke. Estimates were derived from a logistic regression model, adjusting for age and sex. In order to scale all outcomes such that a higher OR indicates increased morbidity, the outcome for hematocrit was reversed (ie, an association with low hematocrit corresponds to an OR > 1). Yellow shading indicates nominal significance (P < .05); red indicates significance after adjusting for false discovery rate (FDR-adjusted P < .05) [Color figure can be viewed at wileyonlinelibrary.com] Examining other SCD modifiers, we found that elevated WBC was associated with reduced hematocrit and increased rates of priapism ( Figure 1B ). Higher hematocrit predicted increased rates of pain crisis ( Figure 1C) , consistent with previous studies associating hematocrit with increased blood viscosity, 15 and smoking strongly predicted increased rates of ACS and leukocytosis ( Figure 1E ). 16 Altogether, these results confirm and add finer resolution to the effects of 5 modifiers on specific aspects of SCD morbidity.
Next, we leveraged the comprehensive kinship information in our full cohort (n = 1210) to estimate the heritability of 20 SCD-relevant traits, including HbF and WBC. Using a variance components model with fixed effects of SCD status, sickle trait status, age, and sex (Appendix in Supporting Information), we found that most hematologic markers exhibited substantial heritable components ( Figure 2A , Table 1 ). Strikingly, HbF and WBC were among the most heritable traits studied, with heritability estimates of 31.6% (±5.4%) and 41.2%
(±6.8%), respectively, demonstrating that even after accounting for the significant influence of SCD, 31.6% and 41.2% of the residual phenotypic variation in HbF and WBC can be explained by other genetic factors in families with SCD transmission.
Finally, we used a bivariate restricted maximum-likelihood procedure 17 to estimate genetic correlations between HbF and WBC and other hematologic traits (Appendix in Supporting Information). We Heritability, or the fraction of phenotypic variance attributable to genetic factors, quantifies the genetic contribution to a trait and forms the foundation for studying the genetic architecture of complex diseases. 18, 19 Genome-wide association studies (GWAS) have emerged as powerful tools for heritability estimation, but an outstanding issue with this approach is that a substantial fraction of heritability cannot be captured by GWAS variants at insufficient sample sizes. 20 Thus, an important advantage of estimating heritability from family-based cohorts, as performed here, is that it infers the expected genetic relatedness from known relationships and does not suffer from missed heritability. As recent studies have employed similar approaches using large electronic health records to estimate the heritability of other phenotypes, 19 we suspect our approach will be applicable to understanding variance among other Mendelian and complex phenotypes.
Previous family-based studies have measured genetic contributions to HbF and HbF-producing cells. [21] [22] [23] These examined either healthy populations or twins with SCD, but none have incorporated both individuals with SCD and healthy carriers (Table S4 in Supporting Information). Of note, it is difficult to study HbF in healthy cohorts, since the near-zero HbF levels of non-anemic individuals cannot be sensitively measured. In contrast, our study leveraged a large cohort of related individuals both with SCD and without to directly measure the heritability of HbF, which provides a more clinically relevant estimate. Our estimates demonstrate the value of studying heritability in the context of inheritance from healthy carriers to SCD patients,
showing that genetic factors continue to influence HbF and other hematologic traits outside of the inherited effects of SCD itself.
In sum, this study utilized a large cohort of SCD patients and family members to measure the heritability of 20 hematologic traits. We find that surprisingly, genetic variation can explain 31.6% and 41.2% of this cohort's variance in HbF and WBC, even after accounting for the effects of SCD transmitted from carrier parents to children with SCD. More broadly, these results suggest that family-based studies will be valuable for gaining further insights into the susceptibility of clinically heterogeneous disorders such as SCD and their underlying genetic modifiers.
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